Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA

Kyle J MacBeth,Vivek S Chopra, Lin Tang, Bing Zheng,Brian Avanzino,Wendy L See,Martin Schwickart,Maria E Figueroa,Lynn Quek,Jorge F DiMartino

Experimental Hematology（2021）

引用 5|浏览3

暂无评分

摘要

•Enasidenib is an inhibitor of mutant IDH2 that releases the block in cellular differentiation imposed by aberrant production of 2-hydroxyglutarate.•Mechanisms of action of azacitidine and enasidenib involve regulation of the epigenome.•The enhanced anti-leukemic activity of combining azacitidine and enasidenib leads to greater reductions in DNA methylation.

查看译文

关键词

DNA methylation,IDH2,acute myeloid leukemia,azacitidine,enasidenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要